Theoretically, early reduction of apoB-containing lipoproteins to very low levels could potentially eliminate cardiovascular disease; however, this strategy currently faces practical limitations due to issues like low compliance and adverse effects in certain individuals32. The gene discussed is APOB; the disease is cardiovascular disorder.